Vitamins as modulators of Deltaretrovirus infection: implications for HTLV-1 and bovine leukemia virus-associated diseases Authors: Mohammad Mehdi Akbarin, Zahra Farjami, Hugo Ramírez Álvarez Published: 2026 ABSTRACT AbstractDeltaretroviruses, particularly human T-cell leukemia virus type 1 (HTLV-1) and bovine leukemia virus (BLV), are oncogenic retroviruses responsible for severe lymphoproliferative and inflammatory diseases, including adult T-cell leukemia/lymphoma (ATLL) and HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite decades of research, effective curative therapies remain limited, and disease progression is strongly influenced by host immune and metabolic factors. Accumulating evidence indicates that vitamins play critical roles in modulating viral pathogenesis, immune dysregulation, oxidative stress, and tissue damage in Deltaretrovirus infections. Clinical, experimental, and genetic studies demonstrate that deficiencies or altered signaling of vitamins D, C, and B complex are associated with increased disease susceptibility, inflammatory severity, and neurological or hematological complications in HTLV-1–infected individuals. Vitamin D signaling, in particular, has been linked to immune regulation, control of proviral load, and genetic susceptibility via vitamin D receptor polymorphisms. Antioxidant vitamins, such as vitamin C, exert pro-apoptotic effects in HTLV-1–transformed cells, while vitamin B derivatives improve neurological function and quality of life in HAM/TSP patients. Emerging data also suggest parallels in BLV infection, including vitamin-related metabolic alterations and potential zoonotic implications. This review synthesizes current evidence on the role of vitamins in Deltaretrovirus infection, highlights mechanistic and clinical insights, and identifies critical knowledge gaps. Understanding vitamin-dependent pathways may support the development of adjunctive, low-cost strategies to improve disease outcomes in HTLV-1– and BLV-associated disorders.Keywords: Deltaretrovirus, HTLV-1, BLV, Vitamins, Adult T-cell leukemia/lymphoma, HAM/TSP, Immune modulation Introduction Delta-retrovirus infections represent a significant public health and veterinary concerns due to their ability to establish lifelong infections and promote oncogenic outcomes (SAEEDI-MOGHADDAM et al., 2024; Ramezani et al., 2022). Members of the Deltaretrovirus genus chronically infect lymphocytes, with lifelong persistence and potential serious consequences in a subset of infected hosts. Human T-lymphotropic virus type 1 (HTLV-1) and Bovine leukemia virus (BLV) are representative members of the genus Deltaretrovirus within the family Retroviridae (Branda et al., 2025; Hossain et al., 2025). Deltaretroviruses are complex retroviruses characterized by persistent infection, integration of proviral DNA into the host genome, long latency periods, and the ability to induce chronic inflammatory and neoplastic diseases (HRON et al., 2019). HTLV-1 primarily infects CD4⁺ T lymphocytes in humans, whereas BLV predominantly infects B lymphocytes in cattle and is the etiological agent of enzootic bovine leukosis (Ramezani et al., 2022; Hossain et al., 2025). Despite differences in host species and cellular tropism, HTLV-1 and BLV share important biological features, including similar genomic organization, regulatory viral proteins, clonal expansion of infected cells, immune dysregulation, and leukemogenic potential (Hossain et al., 2025, AKBARIN et al., 2025). These shared characteristics make HTLV-1 and BLV valuable comparative models for understanding Deltaretrovirus pathogenesis and host immune modulation. Among Deltaretroviruses, HTLV-1 alone infects millions worldwide and is endemic in regions of Japan, the Caribbean, Central and South America, and parts of Africa, where it contributes to both hematologic malignancy and neurologic disease burden (Mahdifar et al., 2023; Ramezani et al., 2022). HTLV-1 is the most extensively studied human pathogen, with well-documented associations with adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (AKBARIN et al., 2013; Ramezani et al., 2022). ATLL is an aggressive malignancy of CD4 + T cells, while HAM/TSP is a chronic, progressive neurologic disorder, both of which arise decades after persistent infection in a minority of carriers (Branda et al., 2025; Ramezani et al., 2022). In contrast, other HTLV types (e.g., HTLV-2) show lower pathogenic potential, and rarer types (HTLV-3/−4) remain poorly characterized but reflect ongoing viral diversity within primate hosts (Branda et al., 2025). BLV is a closely related Deltaretrovirus that causes enzootic bovine leukosis, a B-cell neoplastic disease in cattle (Khatami et al., 2020; SAEEDI-MOGHADDAM et al., 2024). Like HTLV-1, BLV establishes a lifelong infection with a long latent period preceding disease and shares molecular mechanisms of proviral integration and host-immune interaction (AKBARIN et al., 2025; Ashrafi et al., 2021). Recently, compelling molecular studies have detected BLV DNA and proteins in human breast tissue and associated BLV presence with increased prevalence in breast cancer cases, raising questions about zoonotic potential and the role of foodborne exposure to dairy and beef products in human infection (LAWSON et al., 2018; SAEEDI-MOGHADDAM et al., 2024). Although definitive causal links to human oncogenesis remain under investigation, these findings underscore the broader significance of Deltaretrovirus biology across species (LAWSON et al., 2018). Vitamins are essential organic micronutrients required in small amounts for normal cellular metabolism, immune regulation, antioxidant defense, and tissue homeostasis (Peterson et al., 2020; Nandagopal and Manickam, 2026). In humans and animals, thirteen major vitamins have been identified and are broadly classified into fat-soluble vitamins (A, D, E, and K) and water-soluble vitamins (vitamin C and the B-complex vitamins) (Vlasova et al., 2016, ALI et al., 2024; Goluch et al., 2025). These micronutrients function as enzymatic cofactors, transcriptional regulators, antioxidants, and signaling molecules that influence cellular proliferation, differentiation, apoptosis, and inflammatory responses. The host immune response to viral infection is shaped by both innate and adaptive factors, among which micronutrients such as vitamins play essential roles. Vitamins, particularly vitamin D, A, E, and C, modulate immune cell development, cytokine production, and pathogen defense pathways (Fink et al., 2025; RIZWAN et al., 2025). Vitamins A and D regulate innate and adaptive immune responses through modulation of cytokine production, T-cell differentiation, and transcriptional signaling pathways (Arora et al., 2022; Penkert et al., 2016). Vitamin D, for example, regulates both innate antimicrobial peptide expression and adaptive immune functions, and deficiency has been associated with increased susceptibility to and severity of various viral infections (RIZWAN et al., 2025). In Human immunodeficiency virus type 1 (HIV-1) infection, another chronic retroviral condition, observational studies link low vitamin D levels with poorer immune markers and outcomes, highlighting broad immunomodulatory roles of vitamins in retroviral pathogenesis (Webb et al., 2009; FORRESTER et al., 2009). Vitamin A is another essential immunomodulatory micronutrient that plays fundamental roles in maintaining epithelial barrier integrity, regulating innate and adaptive immune responses, and controlling lymphocyte differentiation and function. Its active metabolite, retinoic acid, regulates gene transcription through retinoic acid receptors (RARs), thereby influencing dendritic cell maturation, T-cell polarization, regulatory T-cell development, B-cell function, and cytokine production (Arora et al., 2022; Penkert et al., 2016). Vitamin A deficiency has been associated with impaired antiviral immunity, increased susceptibility to infectious diseases, and dysregulated inflammatory responses, highlighting its importance in host defense against viral pathogens (Arora et al., 2022; Fink et al., 2025). Vitamin C contributes to antiviral defense by reducing oxidative stress and enhancing immune cell function (Fink et al., 2025), whereas B-complex vitamins participate in cellular metabolism, mitochondrial activity, and neuronal maintenance (Kira, 2013). Dysregulation or deficiency of these vitamins has been associated with increased susceptibility to multiple viral infections, including HIV, hepatitis viruses, influenza, Epstein–Barr virus, and herpesviruses. In the context of Deltaretrovirus infection, accumulating evidence suggests that vitamins influence viral pathogenesis, immune-mediated tissue injury, leukemogenesis, and neurological complications associated with HTLV-1 and BLV infection (Derakhshan et al., 2020; Netto et al., 2021; Lian et al., 2025). Therefore, this review focuses primarily on vitamins A, D, C, and B-complex vitamins because of their emerging roles in viral persistence, immune modulation, oxidative stress regulation, and disease progression in HTLV-1 and BLV-associated disorders. Despite recognition of vitamins’ importance in general viral immunobiology, gaps remain regarding their specific roles in Deltaretrovirus infection and pathogenesis. Limited studies have examined whether vitamins modify host susceptibility, viral replication, immune dysregulation, or oncogenic progression in HTLV-1 or BLV, and few clinical or mechanistic investigations have clarified causal relationships. Addressing this gap is critical, particularly given emerging zoonotic concerns about BLV and the lack of targeted therapeutics or vaccines for most Deltaretroviruses. Therefore, the present study aims to investigate the role of selected vitamins in modulating delta-retroviral infection dynamics, immune responses, and disease outcomes, advancing understanding of nutritional-immune interactions in retroviral pathogenesis and informing potential adjunctive strategies for disease prevention and management. Role of vitamins in modulating immune responses during Deltaretrovirus infection Nutritional status, particularly vitamin availability, is increasingly recognized as an important determinant of host immune responses during chronic viral infections. In the context of bovine leukemia virus (BLV), which establishes lifelong infection and can lead to enzootic bovine leukosis, limited but informative evidence suggests that vitamins, especially vitamin A, can significantly influence antiviral immunity and viral persistence. The most direct evidence linking vitamins to BLV infection is provided by Miyauchi et al. (2021), who investigated the immunological consequences of dietary vitamin A restriction in beef cattle naturally infected with BLV (Miyauchi et al., 2021). This study demonstrated that cattle maintained on vitamin A-restricted diets exhibited enhanced BLV-specific T-cell responses, including increased interferon-γ production and heightened cellular immune activity (Miyauchi et al., 2021). Importantly, these immunological changes were associated with a significant reduction in BLV proviral load, indicating improved control of viral replication at the host level (Miyauchi et al., 2021). The findings suggest that excessive vitamin A intake may suppress effective antiviral cellular immunity, whereas controlled restriction can restore immune competence against BLV. From a mechanistic perspective, the authors proposed that vitamin A influences the balance between immune tolerance and effector responses. Retinoic acid, the active metabolite of vitamin A, is known to promote regulatory T-cell differentiation and immune homeostasis (Miyauchi et al., 2021). In the setting of BLV infection, this immunoregulatory effect may inadvertently favor viral persistence by dampening cytotoxic T-lymphocyte responses required for proviral control. The observed enhancement of antiviral immunity under vitamin A restriction supports the hypothesis that vitamin-mediated immune modulation plays a critical role in BLV pathogenesis and disease progression. Proteomic and metabolomic evidence further suggests that BLV infection disrupts several vitamin-associated metabolic and antioxidant pathways that may contribute to leukemogenesis. Reichert (2017) identified dysregulation of proteins involved in immune signaling, oxidative stress regulation, and cellular metabolism in BLV-induced leukemic B cells, indicating profound metabolic reprogramming during viral transformation. In addition, Lian et al. (2025) demonstrated that BLV infection alters ferroptosis-related pathways, including glutathione metabolism, lipid peroxidation control, and antioxidant defense mechanisms. These pathways are closely associated with vitamin-dependent enzymes and cofactors, particularly vitamin B6–related reactions involved in amino acid metabolism, redox homeostasis, and lipid metabolism. Disruption of these antioxidant and metabolic pathways may reduce apoptosis, enhance survival of infected cells, and promote chronic viral persistence and leukemogenic progression. Although direct characterization of specific vitamin-regulated proteins in BLV infection remains limited, current findings support an important role for vitamin-associated metabolic pathways in BLV pathogenesis. The apparently contrasting effects of vitamin A in BLV and HTLV-1 infections likely reflect differences in host-cell tropism, immune microenvironment, and disease pathogenesis rather than major differences in viral structure alone. BLV primarily infects B lymphocytes in cattle, whereas HTLV-1 predominantly targets CD4⁺ T lymphocytes in humans (AKBARIN et al., 2025; Ramezani et al., 2022). In BLV infection, dietary vitamin A restriction enhances BLV-specific cellular immune responses, including IFN-γ production and cytotoxic T-cell activity, resulting in lower proviral load (Miyauchi et al., 2021). These findings suggest that excessive retinoic acid–mediated immune regulation may suppress effective antiviral immunity in BLV-infected cattle. In contrast, in HTLV-1–associated adult T-cell leukemia/lymphoma, retinoic acid and synthetic retinoids directly inhibit proliferation of malignant T cells, suppress CD25 expression, interfere with Tax-associated signaling pathways, and induce apoptosis (MALONEY et al., 2003). Therefore, the beneficial effects of vitamin A in HTLV-1 appear to result primarily from direct antitumor activity rather than enhancement of antiviral immune responses. Similar differences may also exist for vitamin D, which has a well-established immunomodulatory and pathogenic role in HTLV-1–associated diseases, whereas its role in BLV infection remains poorly characterized (Sagara et al., 2024; RIZWAN et al., 2025). These observations highlight important host- and cell-type specific differences in vitamin-mediated regulation of Deltaretrovirus pathogenesis. Overall, current evidence linking vitamins to BLV infection is sparse and largely focused on vitamin A, highlighting a significant gap in knowledge about the roles of other vitamins, such as D, E, and C, in BLV immunity and oncogenesis. Given the immunomodulatory properties of these vitamins and their established roles in other chronic viral infections (Fig. 1), further studies are warranted to systematically evaluate how vitamin status influences BLV proviral load, immune dysregulation, and progression to enzootic bovine leukosis. Addressing this gap may yield novel nutritional or adjunctive strategies to control BLV infection at the population and individual-animal levels. Immunomodulatory role of vitamin A (retinoic acid) in bovine leukemia virus (BLV) infection. This schematic illustrates the proposed effects of vitamin A (retinoic acid) on host immune cell subsets and antiviral responses during BLV infection. Vitamin A is shown as retinoic acid, highlighting its bioactive form, which regulates immune signaling via retinoic acid receptors. Extracellular BLV particles interact with cellular receptors at the plasma membrane, where viral envelope-mediated membrane fusion results in release of the viral core into the cytoplasm. Following reverse transcription and proviral integration, viral proteins are synthesized intracellularly, while mature virions are assembled and released from infected cells. Vitamin A (retinoic acid) diffuses into the cell and binds nuclear retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimers, which regulate transcription of immune-response genes. HTLV-1 entry is initiated by receptor binding and membrane fusion at the plasma membrane, followed by release of the viral core into the cytoplasm. The subsequent steps of reverse transcription, proviral integration, and viral gene expression are illustrated according to the established HTLV-1 replication cycle. BLV-specific cytotoxic T lymphocytes (CTLs) are depicted as activated effector cells with abundant cytoplasmic granules, reflecting enhanced cytotoxic activity and increased production of interferon-gamma (IFN-γ), which contribute to antiviral defense and viral load control. BLV-specific T helper (Th) cells support CTL responses and B-cell–mediated immunity through cytokine secretion and cell–cell interactions. In contrast, regulatory T cells (Tregs) are shown to have reduced frequency or suppressive activity, consistent with a shift away from immunosuppression toward effective antiviral immunity. Directional arrows indicate the immunological crosstalk between infected B cells and T-cell subsets, while upward and downward arrows denote relative increases or decreases in cytokine production, immune activation, or cell populations. Overall, the figure summarizes how vitamin A–mediated immune modulation may enhance BLV-specific cellular immune responses, promote IFN-γ production, and contribute to improved control of BLV infection Role of vitamins in human T-lymphotropic virus type one (HTLV-1) infection and pathogenesis Early experimental evidence indicates that HTLV-1 infection directly interferes with host vitamin metabolism, particularly with vitamin D pathways. Reichel et al. (1987) demonstrated that HTLV-transformed human lymphocytes actively metabolize 25-hydroxyvitamin D₃, exhibiting altered vitamin D metabolism compared with non-transformed cells (Reichel et al., 1987). The authors showed that HTLV-infected T cells possess the enzymatic capacity to convert vitamin D metabolites, suggesting that viral transformation reprograms host endocrine-immune interactions (Reichel et al., 1987). This finding provided one of the first mechanistic links between HTLV-1 infection and dysregulated vitamin D signaling, implicating vitamin D pathways in viral persistence and leukemic transformation. Building on these observations, INOUE et al. (1993) investigated the effects of 22-oxacalcitriol, a non-hypercalcemic analog of calcitriol, in HTLV-1-infected T cells (INOUE et al., 1993). Their study demonstrated that this vitamin D analog significantly suppressed cellular proliferation and downregulated parathyroid hormone–related peptide (PTHrP) gene expression, a factor implicated in HTLV-1–associated malignancy and hypercalcemia (INOUE et al., 1993). Importantly, these antiproliferative effects occurred without inducing hypercalcemia, highlighting the therapeutic potential of vitamin D derivatives in HTLV-1–driven T-cell dysregulation and oncogenesis. In addition to vitamin D, epidemiological evidence supports a role for vitamin A in modulating outcomes of HTLV-1 infection. MALONEY et al. (2003) examined HTLV-1-infected Jamaican children and reported that low serum vitamin A levels were significantly associated with higher HTLV-1 proviral load (MALONEY et al., 2003). This inverse relationship suggests that vitamin A deficiency may impair immune control of HTLV-1 replication, leading to increased viral burden (MALONEY et al., 2003). The findings underscore the importance of adequate vitamin A status in maintaining antiviral immune responses during chronic HTLV-1 infection, particularly in pediatric populations. A mechanistic link between HTLV-1 and vitamin C biology was proposed by MONTEL-HAGEN et al. (2008), identified GLUT1, the primary cellular receptor for HTLV-1, as a glucose transporter intricately connected to vitamin C transport and metabolism (MONTEL-HAGEN et al., 2008). The authors highlighted that humans’ inability to synthesize vitamin C, combined with HTLV’s reliance on GLUT1 for cell entry, may create a metabolic intersection among viral infection, glucose uptake, and vitamin C availability (MONTEL-HAGEN et al., 2008). Although largely conceptual, this work suggests that vitamin C homeostasis may influence HTLV-1 entry or replication indirectly through metabolic and transporter-dependent pathways. Collectively, these studies demonstrate that HTLV-1 infection is closely intertwined with host vitamin biology at multiple levels, including vitamin metabolism, immune regulation, viral replication, and cellular proliferation (Fig. 2). Vitamin D and its analogs exhibit direct antiproliferative effects in HTLV-1-infected cells, whereas deficiencies in vitamins A and, potentially, C are associated with higher viral burden or altered host–virus interactions (Fig. 2). Despite these insights, clinical and mechanistic studies remain limited, highlighting a critical gap in understanding how targeted vitamin modulation could be leveraged to control HTLV-1 infection or prevent HTLV-1-associated diseases. Roles of vitamins A, C, and D in the regulation of immune responses and viral dynamics during Human T-cell leukemia virus type 1 (HTLV-1) infection. This schematic summarizes the immunomodulatory and antiviral effects of selected vitamins on HTLV-1 entry, replication, and host T-cell responses. Vitamin A (retinoic acid) diffuses across the plasma membrane and binds cytoplasmic retinoic acid receptors (RARs). The ligand-bound RAR subsequently heterodimerizes with RXR and translocates into the nucleus, where the complex binds retinoic acid response elements (RAREs) to regulate transcription of immune-response genes. It cooperates with T-cell receptor (TCR) signaling to regulate transcription factor (TF) activity and cytokine gene expression, including interleukin-2 (IL-2). Adequate vitamin A levels promote proliferation, differentiation, and functional maintenance of CD4⁺ helper T cells in response to antigenic stimulation. In contrast, vitamin A deficiency impairs CD4⁺ T-cell proliferation and reduces the pool of effective T-helper cells, weakening antiviral immune control and thereby contributing to increased HTLV-1 proviral load (PVL). Vitamin C is depicted in its oxidized form, dehydroascorbic acid (DHA), which serves as a substrate for the glucose transporter GLUT1. Because GLUT1 is also a critical entry receptor for HTLV-1, competition between DHA and the virus for GLUT1 uptake may interfere with viral entry into target T cells. This mechanism may limit HTLV-1 infection and is associated with reduced viral load. Vitamin D3 is shown to undergo hydroxylation to its active form, 1,25-dihydroxyvitamin D3 [1,25(OH)₂D₃], which can further modulate immune signaling pathways and viral gene expression, including effects on the HTLV-1 transactivator protein Tax. HTLV-1 particles are shown extracellularly. Following receptor binding and membrane fusion, only the viral core enters the cytoplasm, where reverse transcription occurs before nuclear import and proviral integration. Dashed arrows indicate regulatory or indirect interactions, while upward and downward arrows represent relative increases or decreases in immune activity, viral replication, or metabolite levels. Collectively, the figure highlights how vitamins A, C, and D influence T-cell immunity, viral entry, and proviral burden during HTLV-1 infection Role of vitamins in HTLV-1 infection, cellular transformation, and immune dysregulation, in-vitro studies A substantial body of experimental evidence demonstrates that vitamins, particularly vitamin D and vitamin A derivatives, play critical roles in regulating cellular proliferation, immune signaling, and oncogenic processes relevant to HTLV-1 infection. Early studies established that vitamin D signaling directly modulates lymphocyte function, creating a biological framework for its involvement in HTLV-1-associated disease. Tobler et al. (1987) showed that 1,25-dihydroxyvitamin D₃ regulates granulocyte–macrophage colony-stimulating factor (GM-CSF) expression in normal human peripheral blood lymphocytes through receptor-mediated mechanisms (Tobler et al., 1987). Because GM-CSF is implicated in T-cell activation and proliferation, these findings provided an early mechanistic basis for vitamin D–dependent control of immune pathways that are frequently dysregulated in HTLV-1 infection and ATLL (Tobler et al., 1987). Defects in vitamin D receptor (VDR) signaling further highlight the importance of intact vitamin D pathways in T-cell biology. KOEFFLER et al. (1990) demonstrated that lymphocyte cell lines derived from patients with vitamin D–dependent rickets type II exhibited functional abnormalities in the VDR, resulting in impaired responses to 1,25-dihydroxyvitamin D₃ (KOEFFLER et al., 1990). These findings are highly relevant to HTLV-1 pathogenesis, as ATLL cells often display resistance to growth-inhibitory signals, suggesting that altered vitamin D responsiveness may contribute to uncontrolled proliferation in HTLV-1-infected T cells (KOEFFLER et al., 1990). Direct links between vitamin D signaling and HTLV-1 oncogene expression were provided by SANTIAGO et al. (1992), who used HTLV-1 Tax transgenic mice to demonstrate osteoclast-restricted and vitamin D–dependent expression of the Tax oncoprotein (SANTIAGO et al., 1992). Their results showed that vitamin D regulates Tax expression in bone-associated cells, establishing a tissue-specific interaction between vitamin D signaling and HTLV-1 oncogenic activity (SANTIAGO et al., 1992). This study provided critical in-vivo evidence that vitamin D can influence HTLV-1 gene expression in a cell-type-dependent manner. Several studies have demonstrated potent antiproliferative effects of vitamin D and its analogs on leukemic T cells. Elstner et al. (1994) reported that 1α,25-dihydroxy-20-epi-vitamin D₃ is an exceptionally strong inhibitor of leukemic cell growth in vitro, including T-cell malignancies relevant to HTLV-1–associated ATLL (Elstner et al., 1994). These growth-inhibitory effects occurred at low concentrations, underscoring the therapeutic potential of vitamin D analogs in HTLV-1-related leukemia (Elstner et al., 1994). In contrast, Geffner et al. (1996) showed that insulin-like growth factor I (IGF-I) does not mediate T-lymphoblast colony formation in response to 1,25(OH)₂ vitamin D₃ or other hormones, indicating that vitamin D’s effects on T-cell proliferation are IGF-I independent and mediated through distinct intracellular pathways (Geffner et al., 1996). Vitamin A derivatives (retinoids) have also been shown to modulate HTLV-1–infected T-cell behavior. MIYATAKE and MAEDA (1997) demonstrated that retinoic acid inhibits proliferation and downregulates CD25 (IL-2 receptor α chain) expression in adult T-cell leukemia cells, indicating suppression of IL-2–dependent growth signaling (MIYATAKE and MAEDA, 1997). These findings were extended by Darwiche et al. (2007), who showed that the synthetic retinoid (4-hydroxyphenyl) retinamide induces reactive oxygen species (ROS)–mediated apoptosis in malignant T cells, an effect that is partially counteracted by the HTLV-1 Tax oncoprotein (Darwiche et al., 2007). This study highlighted Tax-mediated resistance to vitamin-induced oxidative cell death as a mechanism of viral oncogenic persistence. Similarly, PARRA and GUTIERREZ (2013) demonstrated that all-trans retinoic acid inhibits the growth of Tax-activated Jurkat T cells via a mechanism requiring JNK-1 inhibition, further confirming that retinoids interfere with HTLV-1–driven signaling cascades (PARRA and GUTIERREZ, 2013). The role of vitamin-associated redox regulation in HTLV infection has been further supported by studies on oxidative stress pathways. MASUTANI et al. (2005) reviewed the thioredoxin system in retroviral infection and apoptosis, emphasizing its importance in regulating redox balance, cell survival, and viral replication (MASUTANI et al., 2005). Given that several vitamins (notably vitamins A, C, and E) interact with cellular redox systems, this work provides a mechanistic context for how vitamin-regulated antioxidant pathways may influence HTLV-1–associated cell survival and immune evasion. In line with this concept, HARAKEH et al. (2006) showed that Epican Forte, a micronutrient-based compound rich in antioxidant vitamins, induces apoptosis in both HTLV-1–positive and HTLV-1–negative malignant T cells, supporting a role for vitamin-mediated oxidative mechanisms in controlling HTLV-1-related malignancy (HARAKEH et al., 2006). More recently, the immunomodulatory effects of vitamin D in HTLV-1 infection have been directly examined. HUANG et al. (2022) evaluated the impact of 1,25-dihydroxyvitamin D₃ on T-helper 17 (Th17) cells and regulatory T cells (Tregs) in HTLV-1-infected cell lines. Their results demonstrated that vitamin D suppresses Th17 differentiation while promoting Treg development, suggesting that vitamin D contributes to immune balance during HTLV-1 infection (HUANG et al., 2022). This finding is particularly relevant to HTLV-1–associated inflammatory and neurodegenerative conditions, where Th17/Treg imbalance plays a pathogenic role. Collectively, these studies demonstrate that vitamins, especially vitamin D and vitamin A derivatives, interact with HTLV-1 infection at multiple levels, including viral oncogene expression, leukemic cell proliferation, immune regulation, oxidative stress, and apoptosis. While vitamin D analogs and retinoids consistently exhibit antiproliferative and immunomodulatory effects in HTLV-1–related models, viral factors, such as Tax, can partially counteract these pathways, highlighting the complex interplay between host micronutrients and viral oncogenesis. These findings underscore the therapeutic and preventive potential of targeting vitamin-dependent pathways in HTLV-1 infection, while also revealing critical gaps that warrant further translational and clinical investigation. Role of vitamins and vitamin-related pathways in the treatment and pathogenesis of adult T-cell leukemia/lymphoma Emerging evidence indicates that vitamin-dependent pathways play important roles in the pathogenesis and potential treatment of HTLV-1–associated ATLL. One of the most mechanistically informative studies was conducted by NISHINAKA et al. (2004), who investigated thioredoxin-binding protein-2 (TBP-2), also known as vitamin D₃ up-regulated protein 1 (VDUP1), in HTLV-1–dependent T-cell transformation (NISHINAKA et al., 2004). The authors demonstrated that VDUP1 expression was markedly reduced or lost in HTLV-1–transformed T cells. Restoration of VDUP1 suppressed cell growth and induced apoptosis, indicating that loss of vitamin D–responsive redox regulation contributes to leukemogenesis. These findings established a direct molecular link between vitamin D signaling, redox homeostasis, and ATLL development. In parallel, experimental studies have shown that vitamin C (ascorbic acid) exerts direct antileukemic effects in ATLL. HARAKEH et al. (2007) demonstrated that pharmacological concentrations of ascorbic acid induce dose-dependent apoptosis in ATLL cells through mechanisms involving oxidative stress, mitochondrial dysfunction, and activation of caspase-dependent cell death pathways. Importantly, ATLL cells were more sensitive to ascorbic acid–induced apoptosis than non-malignant lymphocytes, suggesting a degree of therapeutic selectivity (HARAKEH et al., 2007). This study supports the concept that vitamin C may serve as a pro-oxidant therapeutic agent in HTLV-1–associated leukemia. More recently, clinical correlations between vitamin D status and HTLV-1–associated disease severity have been reported. Sagara et al. (2024) evaluated plasma 25-hydroxyvitamin D levels in individuals with HTLV-1 infection and demonstrated that lower vitamin D levels were significantly associated with ATLL and other HTLV-1–associated diseases, compared with asymptomatic carriers (Sagara et al., 2024). The study suggested that vitamin D deficiency may contribute to immune dysregulation, disease progression, or reduced control of HTLV-1–driven malignancy, positioning vitamin D status as a potential biomarker of disease risk and progression (Sagara et al., 2024). Collectively, these studies indicate that vitamins influence ATLL at multiple levels, including molecular regulation of leukemic transformation (vitamin D/VDUP1), induction of apoptotic cell death (vitamin C), modulation of tumor invasiveness (nutrient-dependent MMP regulation), and clinical disease susceptibility (vitamin D deficiency) (SEYMOUR et al., 1994) (Table 1). Although clinical trials are lacking, the accumulated evidence supports further investigation of vitamin-based or vitamin-adjunctive strategies as supportive or targeted therapeutic approaches in HTLV-1–associated ATLL. Table 1Role of vitamins in HTLV-1–associated ATLLReferencesVitamin/NutrientStudy TypeModel/PopulationMain FindingsRelevance to ATLL(NISHINAKA et al., 2004)Vitamin D–related protein (VDUP1/TBP-2)Experimental (in vitro, mechanistic)HTLV-1–transformed T-cell linesVDUP1 expression lost in HTLV-1–transformed cells; restoration suppressed proliferation and induced apoptosis via redox regulationDirect molecular link between vitamin D signaling, redox imbalance, and ATLL leukemogenesis(HARAKEH et al., 2007)Vitamin C (Ascorbic acid)Experimental (in vitro)ATLL cell lines vs. non-malignant lymphocytesHigh-dose vitamin C induced dose-dependent apoptosis via oxidative stress, mitochondrial dysfunction, and caspase activation; ATLL cells were more sensitiveSupports vitamin C as a potential pro-oxidant antileukemic agent(Sagara et al., 2024)Vitamin D (25-hydroxyvitamin D)Observational clinical studyHTLV-1–infected individuals (ATLL, other HTLV-1 diseases, asymptomatic carriers)Lower vitamin D levels were associated with ATLL and other HTLV-1–associated diseasesVitamin D deficiency as biomarker of ATLL risk and disease progression(SEYMOUR et al., 1994)Indirect (vitamin D–calcium metabolism context)Clinical case reportATLL patientDocumented metabolic complications including hypercalcemia in ATLLProvides clinical context for vitamin D–calcium pathway dysregulation in ATLL Role of vitamins in HTLV-1–associated ATLL Role of vitamins in the pathogenesis and treatment of HTLV-1–associated HAM/TSP Multiple clinical, genetic, and interventional studies indicate that vitamins play important roles in the pathogenesis, immune dysregulation, and symptomatic treatment of HAM/TSP, a chronic inflammatory neurodegenerative disease caused by HTLV-1 infection. Early therapeutic evidence was provided by KATAOKA et al. (1993), who evaluated intermittent high-dose vitamin C therapy in patients with HAM/TSP (KATAOKA et al., 1993). The study reported clinical improvement in motor function and spasticity in a subset of patients, suggesting that antioxidant therapy may mitigate oxidative stress–mediated neural damage associated with HTLV-1–induced inflammation (KATAOKA et al., 1993). Vitamin B–based interventions have also been explored. Cartier et al. (1996) conducted a randomized trial assessing vitamin B12 in combination with cytidine monophosphate and uridine triphosphate in patients with progressive spastic paraparesis, including HTLV-1–infected individuals (Cartier et al., 1996). The authors reported modest neurological improvement and stabilization of disease progression, supporting a role for vitamin B–related pathways in neuronal function and repair (Cartier et al., 1996). In a broader therapeutic overview, Nakagawa et al. (1996) analyzed outcomes in 200 HAM/TSP patients receiving various treatments, noting that vitamin-based therapies were among the interventions that showed symptomatic benefit, although they did not significantly reduce HTLV-1 proviral load, emphasizing their supportive rather than antiviral role (Nakagawa et al., 1996). Stronger evidence for vitamin B efficacy emerged from Kira (2013), who demonstrated that an oral vitamin B1 (thiamine) derivative significantly improved gait disturbance, spasticity, and motor disability in HAM/TSP patients (Kira, 2013). This study highlighted thiamine’s role in neuronal energy metabolism and suggested that vitamin B1 supplementation can meaningfully improve quality of life in HAM/TSP, even in the absence of direct antiviral effects (Kira, 2013). Beyond treatment, genetic and metabolic studies implicate vitamin D signaling in HAM/TSP susceptibility and disease severity. EIRAKU et al. (2001) and SAITO et al. (2005) independently demonstrated that polymorphisms in the vitamin D receptor (VDR) gene are significantly associated with susceptibility to HAM/TSP among HTLV-1–infected individuals (EIRAKU et al., 2001; SAITO et al., 2005). These findings indicate that host responsiveness to vitamin D modulates immune and inflammatory pathways involved in spinal cord damage. Consistent with these genetic observations, several studies have documented vitamin D deficiency in HAM/TSP patients. Derakhshan et al. (2020) reported abnormally low serum vitamin D levels in HAM/TSP patients, accompanied by dyslipidemia, suggesting systemic metabolic and inflammatory dysregulation (Derakhshan et al., 2020). Netto et al. (2021) further demonstrated that hypovitaminosis D correlates with elevated pro-inflammatory cytokines, including IL-6 and TNF-α, and is significantly associated with HAM/TSP compared with asymptomatic HTLV-1 carriers (Netto et al., 2021). These findings support a model in which vitamin D deficiency exacerbates immune-mediated neural injury. More recently, Sagara et al. (2024) showed that plasma vitamin D levels are inversely correlated with the development of HTLV-1–associated diseases, including HAM/TSP, reinforcing vitamin D’s role as both a biomarker and a potential modifier of disease pathogenesis (Sagara et al., 2024). In parallel, Saghi et al. (2021) expanded the nutritional framework by demonstrating that dietary intake and serum selenium levels influence HTLV-1 infection outcomes, suggesting that vitamin-related micronutrient balance broadly affects immune control and neuroinflammation (Saghi et al., 2021). Finally, comprehensive reviews such as KHAN et al. (2017) have integrated these findings, emphasizing that vitamin deficiencies contribute to oxidative stress, chronic inflammation, and neurodegeneration in HTLV-1–associated neurological disorders, including HAM/TSP (KHAN et al., 2017). Collectively, these studies demonstrate that vitamins, particularly vitamins D, C, and B (B1 and B12), influence HAM/TSP at multiple levels, including disease susceptibility, inflammatory severity, and symptomatic progression (Table 2). While vitamin-based therapies do not eradicate HTLV-1, they represent valuable adjunctive strategies for modulating immune-mediated damage and improving neurological outcomes in HAM/TSP patients. Table 2Role of vitamins and micronutrients in HAM/TSPReferencesVitamin/MicronutrientStudy TypePopulation/ModelMain ResultsRelevance to HAM/TSPNotes(KATAOKA et al., 1993)Vitamin CInterventional clinical studyHAM/TSP patientsImproved motor function and reduced spasticity in subset of patientsAntioxidant therapy may reduce oxidative neural damageSymptomatic benefit(Cartier et al., 1996)Vitamin B12 (+ CMP, UTP)Randomized controlled trialProgressive spastic paraparesis patients (incl. HTLV-1+)Modest neurological improvement and disease stabilizationSupports neuronal repair and functionSupportive therapy(Nakagawa et al., 1996)Multiple vitaminsLarge cohort therapeutic study200 HAM/TSP patientsSymptomatic benefit without proviral load reductionSupportive, not antiviral roleObservational outcomes(Kira, 2013)Vitamin B1 (Thiamine derivative)Interventional clinical studyHAM/TSP patientsImproved gait, spasticity, and motor disabilityEnhances neuronal energy metabolismQuality-of-life improvement(EIRAKU et al., 2001)Vitamin D (VDR polymorphism)Genetic association studyHAM/TSP vs. asymptomatic carriersVDR polymorphisms associated with HAM/TSP susceptibilityHost vitamin D responsiveness affects riskGenetic susceptibility(SAITO et al., 2005)Vitamin D (VDR polymorphism)Genetic association studyHTLV-1–infected individualsVDR polymorphisms linked to HAM/TSP developmentVitamin D signaling modulates neuroinflammationConfirmatory study(Derakhshan et al., 2020)Vitamin DClinical observational studyHAM/TSP patientsLow vitamin D with dyslipidemiaMetabolic and inflammatory dysregulationBiochemical correlation(Netto et al., 2021)Vitamin DClinical observational studyHAM/TSP vs. asymptomatic HTLV-1 carriersHypovitaminosis D associated with high IL-6 and TNF-αExacerbates immune-mediated injuryInflammatory link(Saghi et al., 2021)SeleniumNutritional observational studyHTLV-1–infected individualsDietary intake influenced infection outcomeMicronutrient immune modulationNot a vitamin(KHAN et al., 2017)Multiple vitaminsNarrative reviewHTLV-1 neurological disordersVitamin deficiency linked to oxidative stress and neurodegenerationIntegrative pathogenic modelReview(Sagara et al., 2024)Vitamin DClinical correlation studyHTLV-1–infected individualsLow vitamin D correlated with HAM/TSP developmentVitamin D as biomarker and modifierRecent evidence Role of vitamins and micronutrients in HAM/TSP Conclusion Collectively, available evidence demonstrates that vitamins play multifaceted roles in Deltaretrovirus-associated diseases, influencing viral pathogenesis, host immune responses, oxidative balance, and clinical outcomes. In HTLV-1 infection, vitamin D deficiency and impaired vitamin D receptor signaling are consistently associated with increased susceptibility to ATLL and HAM/TSP, heightened inflammatory responses, and disease progression. Antioxidant vitamins, particularly vitamin C, exhibit direct antileukemic effects in HTLV-1–transformed cells, while vitamin B derivatives contribute to symptomatic improvement in neurological manifestations without directly affecting viral replication. Although vitamin-based interventions do not eliminate Deltaretrovirus infection, they offer meaningful supportive benefits by modulating immune-mediated tissue damage and metabolic dysfunction. Parallel findings in BLV infection further underscore the conserved importance of vitamin-dependent pathways across Deltaretroviruses and raise questions about their zoonotic and metabolic implications. Overall, vitamins represent biologically plausible, accessible, and clinically relevant modulators of Deltaretrovirus-associated disease. Beyond their immunomodulatory and antiviral functions, vitamins may also contribute to disease prevention and long-term management of Deltaretrovirus-associated disorders. Maintenance of adequate vitamin status may help preserve immune homeostasis, reduce oxidative stress, and limit chronic inflammatory responses associated with HTLV-1 and BLV infection. Vitamins with antioxidant and immune-regulatory properties, particularly vitamins A, C, and D, may support antiviral defense mechanisms and potentially reduce progression toward leukemogenesis or neurological complications. In addition, nutritional assessment and targeted vitamin supplementation could serve as supportive adjunctive strategies alongside conventional clinical monitoring and therapeutic interventions. Although current clinical evidence remains limited and further controlled studies are necessary, vitamin-based interventions represent promising complementary approaches for improving disease prevention, immune regulation, and management of Deltaretrovirus-associated diseases. Future perspectives Future research should prioritize well-designed longitudinal and interventional studies to clarify the causal relationships between vitamin status and the progression of Deltaretrovirus disease. Randomized controlled trials are needed to evaluate optimal dosing, safety, and therapeutic efficacy of vitamin D, vitamin C, and vitamin B supplementation as adjunctive treatments in ATLL and HAM/TSP. Mechanistic studies should further dissect vitamin-regulated signaling pathways, including redox balance, immune polarization, and epigenetic regulation of viral transcription. In addition, integrative approaches combining nutritional status, host genetics (e.g., vitamin D receptor polymorphisms), and proviral load measurements may improve risk stratification and personalized management of HTLV-1–infected individuals. Finally, expanding investigations into BLV infection may provide comparative insights into Deltaretrovirus biology and potential cross-species implications. Together, these efforts may establish vitamin-based strategies as evidence-guided components of comprehensive management for Deltaretrovirus-associated diseases. Acknowledgements Mohammad Mehdi Akbarin received financial support from the “Programa de Becas posdoctorales UNAM” DGAPA-UNAM scholarship. Author contributions All authors contributed to the conception of the study, and MMA and HRA designed it. MMA, ZF, and HRA performed data collection and analysis. MMA and ZF wrote the initial draft of the manuscript, and all authors provided comments on subsequent versions. MMA and HRA edited the final draft. All authors read and approved the final manuscript. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare no competing interests. Ethical approval and consent to participate This is an observational study. The UNAM Research Ethics Committee has confirmed that no ethical approval is required for this research. Consent for publication Not Applicable. Clinical trial number not applicable. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.